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Abstract
Quantification of circulating nucleic acids in plasma and serum could be used as a non-invasive diagnostic tool for
monitoring a wide variety of diseases and conditions. We describe here a rapid, simple and accurate multiplex
real-time PCR method for direct synchronized analysis of circulating cell-free (ccf) mitochondrial (mtDNA) and nu-
clear (nDNA) DNA in plasma and serum samples. The method is based on one-step multiplex real-time PCR using a
FAM-labeled MGB probe and primers to amplify the mtDNA sequence of the ATP 8 gene, and a VIC-labeled MGB
probe and primers to amplify the nDNA sequence of the glycerinaldehyde-3-phosphate-dehydrogenase (GAPDH)
gene, in plasma and serum samples simultaneously. The efficiencies of the multiplex assays were measured in se-
rial dilutions. Based on the simulation of the PCR reaction kinetics, the relative quantities of ccf mtDNA were calcu-
lated using a very simple equation. Using our optimised real-time PCR conditions, close to 100% efficiency was
obtained from the two assays. The two assays performed in the dilution series showed very good and reproducible
correlation to each other. This optimised multiplex real-time PCR protocol can be widely used for synchronized quan-
tification of mtDNA and nDNA in different samples, with a very high rate of efficiency.
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Introduction
Eukaryotic cells have nuclear DNA (nDNA) and addi-
tional cytoplasmic mitochondrial DNA (mtDNA). It has
been demonstrated that cell-free nucleic acids, i.e., cell-free
(ccf) nuclear DNA (cf-nDNA) and ccf mtDNA exist in cir-
culation(Sozzietal.,2003).QuantificationofccfnDNAand
ccf mtDNA concentrations in plasma and serum has raised
great interest as a tool for non-invasive diagnosis and moni-
toring of a wide variety of diseases and conditions, such as
cancers (Zhong et al., 2007c), pathological pregnancies
(Zhong et al., 2001), inflammatory disease (Zhong et al.,
2007d) and trauma (Lam et al., 2003). It has been reported
that both circulating plasma nDNA and mtDNA were in-
creased after trauma (Lam et al., 2003; Lam et al., 2004).
Many studies observed elevated levels of ccf nDNA in
plasma or serum of various cancers (Allen et al., 2004;
Gormally et al., 2004; Sozzi et al., 2003; Taback et al.,
2004).ElevatedlevelsofmtDNAweredetectedinplasmaof
prostate cancer patients using quantitative real-time PCR
amplification (Mehra et al., 2007). Recently, Ellinger et al.
(2008) observed that mtDNA in serum of patients with pros-
tate cancer has a predictive value of biochemical recurrence
after prostatectomy. The observations suggested that ccf
DNA might be a potentially valuable prognostic marker for
these patients. The similar increase of ccf mtDNA and ccf
nDNA in cancers, and in patients after trauma, implies that
both the nDNA and mtDNA might be released from the
same tissues of origin and by similar mechanisms. Since the
total amount of mtDNA per cell is unknown, determining
both species in a single reaction would be the most effective
and accurate method to compare relative mtDNA quantities
with nDNA genome equivalents. Furthermore, the multi-
plexed assay for simultaneous testing of two parameters can
reduce the time consumed by the diagnostic procedures.
In our study, we developed a rapid, simple and accu-
rate multiplex real-time PCR method for direct synchro-
nized analysis of mtDNA and nDNA in paired plasma and
serum samples. This method is based on a single-step
real-time PCR, using a FAM- and a VIC-labelled probe for
Genetics and Molecular Biology, 32, 1, 20-24 (2009)
Copyright © 2009, Sociedade Brasileira de Genética. Printed in Brazil
www.sbg.org.br
Send correspondence to Xiao Yan Zhong. Laboratory for Prenatal
Medicine and Gynaecological Oncology, Women’s Hospital, De-
partment of Biomedicine, University of Basel, Hebelstrasse 20, CH
4031 Basel, Switzerland. E-mail: xzhong@uhbs.ch.
Research Articledetermining selected mtDNA and nDNA regions of inter-
est. We optimised the multiplex assays for amplifying
nDNA and mtDNA simultaneously and efficiently. Since
most methods for DNA extraction are established for ex-
tracting and purifying nDNA, in our study we also com-
pared the mtDNA and nDNA quantities by using three
commercial kits for ccf DNA extraction.
Materials and Methods
Sample collection
Pairedplasmaandserumsampleswereobtainedfrom
25 healthy blood donors, with informed consent. The study
was approved by the local institutional review board.
Processing of blood samples
The 10 mL of peripheral blood samples for coagulant
serum and 10 mL of peripheral blood samples for EDTA
plasma were taken from blood donors. The blood samples
wereprocessedimmediatelybycentrifugationat1600gfor
10 min. The plasma and serum layers were transferred to
new Eppendorf tubes and centrifuged again at maximum
speed (16000 g) for 10 min. Plasma and serum samples
were divided into aliquots of 400 L each and stored at
-80 °C.
DNA extraction
SincetherearenocommercialkitsforccfmtDNAex-
traction from serum and plasma, we firstly compared three
different DNA extraction methods for co-extracting nDNA
and mtDNA using plasma and serum samples from five in-
dividuals. DNA extraction from the five paired serum and
plasma samples was performed using the QIAamp DNA
mini kit (QIAGEN) for a first aliquot. For a second aliquot,
we used the High pure PCR template preparation kit
(Roche Applied Science), and for a third aliquot the auto-
matedmethodwiththeMagNAPureLCDNAIsolationKit
– large Volume (Roche Applied Science) and the MagNA
Pure LC Instrument. Visually, the automated method with
MagNA Pure LC DNA Isolation Kit seemed to yield larger
amountsofmtDNAandnDNA,howevernosignificantdif-
ferences were observed in the quantities using the different
commercial kits (Kruskal-Wallis-Test: p = 0.32 for nDNA;
and p = 0.194 for mtDNA, respectively). Using the auto-
mated method, ccf DNA was extracted from each 400 L
plasma and serum sample, and the DNA preparations were
eluted in 100 L elution buffer according to the MagNA
Pure LC software.
Quantitative analysis of ccf DNA in plasma and
serum samples
FiveLofDNAelutionwereusedastemplateforthe
real-time PCR analysis. For testing nDNA, the GAPDH
housekeeping gene was used with forward 5’-CCCCAC
ACACATGCACTTACC-3’andreverse5’-CCTAGTCCC
AGGGCTTTGATT-3’ primers and 5’-MGB-TAGGAAG
GACAGGCAAC – VIC-3’ as the probe. For determining
mtDNA, a sequence of the MTATP 8 gene starting at locus
8446 was amplified, with forward primer 5’-AATATTAA
ACACAAACTACCACCTACC-3’, reverse primer 5’-
TGGTTCTCAGGGTTTGTTATAA-3’ and a 5’-6-FAM-
CCTCACCAAAGCCCATA-MGB-3’ probe (Walker et
al., 2005). PCR was performed using an ABI PRISM 7000
Sequence Detection System (Applied Biosystems, ABI) in
a total reaction volume of 25 L, containing 5 L of DNA,
12.5 L of TaqMan® Universal PCR Master Mix, 4 prim-
ers and 2 probes, using a 2 min incubation at 50 °C, fol-
lowed by an initial denaturation step at 95 °C for 10 min
and40cyclesof1minat60°Cand15sat95°C.Forthesi-
multaneous multiplex TaqMan amplification of the two
species, we optimised the concentration of primers and
probes,whichwere:0.6Mforeachprimerand0.4Mfor
each probe.
Efficiency Measurements of the multiplex assays
The efficiency of the multiplex assay for amplifying
both nDNA and mtDNA was measured with standard
curves generated by dilution series. Two kinds of dilution
series were used for the measurements: 1) HPLC-purified
single-stranded synthetic DNA oligonucleotides (Micro-
synth) specifying a 79-bp mtDNA amplicon and a 97
GAPDH amplicon with 6 concentration points ranging
from5x10
7copiesto5x10
2copies;2)aknownconcentra-
tion of human genomic DNA with six points ranging from
3.125x10
4to10pg/L(including31250,6250,1250,250,
50 and 10 pg/L). The latter dilution series showed higher
reproducible standard dilution curves than the former, and
was therefore used for the further experiments.
Quantitative assessment of ccf mtDNA and nDNA
The concentrations of ccf nDNA were estimated ac-
cording to the standard curves, using the known concentra-
tion of human genomic DNA, and were expressed as ge-
nome-equivalents (GE) per mL of plasma or serum. A
conversionfactorof6.6pgofDNApercellwasusedtocal-
culatetheGE(GarciaMoreiraetal.,2006),asshowninour
previous studies on ccf nDNA (Zhong et al., 2007a; Zhong
et al., 2007b; Zhong et al., 2007c). Fold change of ccf
mtDNA could be calculated using two methods (Liu &
Saint, 2002):
1) 22
 CT
CtnDNA CtmtDNA 

2)
R
R
(1+ E )
(1+ E )
0mtDNA
0nDNA
nDNA
CtnDNA
mDNA
CtmtDNA 
Relative quantities of ccf mtDNA could be estimated
using an equation of GEnDNA x fold-changemtDNA and ex-
pressed also as GE per mL of plasma or serum.
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DatawereanalysedusingtheSPSSsoftware(Statisti-
cal Software Package for Windows v. 15.0). Quantities of
ccf mtDNA and ccf nDNA are expressed as median, range
and fold change. The Spearman Rank Test was applied to
analyse the relationship between mtDNA and nDNA am-
plifications. Mann-Whitney and Krurkal-Wallis tests were
used to determine the statistical significance of the differ-
ences between the measured concentrations of nDNA and
mtDNA.
Results
Optimised experimental design and conditions for
the multiplex assays
Ccf DNA extracted by two different manual methods
and one automated method was amplified and compared
for differences in the quantification of nDNA and mtDNA.
Using the three different kits, it was possible to co-extract
nDNA and mtDNA from plasma and serum samples. The
automated method showed greater advantages, as it proved
lesstime-andlabour-consuming,andminimizedtheriskof
contamination, and was therefore used for further experi-
ments.
The primers and probes for amplifying GAPDH have
been successfully used in our many previous studies, and
the specificity of the assay has been confirmed (Lapaire et
al., 2007; Zanetti-Dallenbach et al., 2007). To assess the
specificity of the assay for amplifying mtDNA, the 0 cell
line without mtDNA was tested. There was no false-posi-
tive amplification for mtDNA in the 0 cells observed
(Xiu-Cheng Fan et al., 2008).
Amplification efficiencies of the multiplex assays
We analysed 10 standard curves, using a known con-
centration of human genomic DNA containing six concen-
tration points for both mtDNA and nDNA. The standard
curves with average slopes at approximately -3.3 (~100%
efficiency) were obtained using our optimised TaqMan
PCR conditions. The two assays on the dilution series were
very similar and showed very good correlation to each
other and reproducibility. The average correlation coeffi-
cient of the 10 standard curves using the Spearman Rank
Test was 0.99 (range: 0.989-0.999, p < 0.001) Figure 1
shows two examples of the standard curves with a correla-
tion coefficient of 0.994 and 0.997, respectively.
Quantitative assessment of ccf nDNA and ccf
mtDNA in serum and plasma
TheccfnDNAequivalentswerecalculatedaccording
to the standardised method, using very reproducible stan-
dard dilution curves, which have been described in our pre-
vious studies (Lapaire et al., 2007; Zanetti-Dallenbach et
al., 2007; Zhong et al., 2007a). Based on the comparative
amplifications of nDNA and mtDNA with an efficiency
close to 100%, the fold changes of ccf mtDNA were calcu-
latedusingtheequationof2
CtnDNA-CtmtDNA(R0mtDNA/R 0nDNA
=( 1+E nDNA)
CtnDNA /( 1+E mtDNA)
CtmtDNA =( 1+
EnDNA)
CtnDNA- CtmtDNA, if EnDNA =E mtDNA;( 1+E nDNA)
CtnDNA-
CtmtDNA 2
CtnDNA-CtmtDNA, if E close to 100%).
The relative equivalents of ccf mtDNA were esti-
mated,andboththequantitiesofccfnDNAandccfmtDNA
inthe20pairedplasmaandserumsamplesareshowninTa-
ble 1.
Ccf mtDNA and nDNA were determined by multi-
plex real-time PCR, with a mean concentration of 208,184
GE/mL and 6,106 GE/mL in the plasma samples, respec-
tively, and of 2,491,364 GE/mL and 273,337 GE/mL in the
serum samples, respectively. The ccf nDNA and ccf
mtDNA levels in the serum samples were significantly
higher than those of the plasma samples (12-45 fold). This
maybearesultofthereleaseofcellularDNAartefactsdur-
ing blood clotting procedures. The ccf mtDNA levels in the
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Figure 1 - Simulation of real-time PCR kinetics for amplifying mtDNA and nDNA on serial dilutions. The figure shows reproducible standard dilution
curves for identification of the mtDNA and nDNA. The upper lines are nDNA standard dilution curves and the lower lines are mtDNA standard dilution
curves. The numbers on the y axis represent the values of cycle threshold (Ct) and numbers on the x axis represent the dilution points.plasma and serum samples were significantly higher than
those of ccf nDNA (9-34 fold).
Discussion
In this study, we described the multiplex assays used
to analyse ccf nDNA and ccf mtDNA simultaneously.
Using the optimised PCR protocol, the amplification of
nDNA and mtDNA in a single reaction tube was very simi-
lar and showed a simulation of real-time PCR kinetics.
With the comparative efficiencies of two assays in a single
tube, we could use the nDNA level as a reference to assess
therelativequantitiesofmtDNA.Themethodissimpleand
does not require generating standard curves, which often
result in errors due to dilution inaccuracy. Using the multi-
plex assays, we could rapidly and accurately determine the
levels of ccf nDNA and ccf mtDNA in serum and plasma
samples.ThelevelsofccfmtDNAincirculationaresignifi-
cantly higher than those of ccf nDNA, due to the fact that
the number of mitochondrial genomes in a cell ranges from
several hundreds to more than 10,000 copies, and each
mitochondrioncontainsbetweentwoand10mtDNAmole-
cules (Higuchi, 2007). The serum samples showed a signif-
icantlyhigherconcentrationofccfDNAbecauseofcellular
DNA release during the blood clotting procedures (Za-
netti-Dallenbach, 2008; Zhong et al., 2007a).
Quantitative alterations of ccf nDNA and mtDNA
have been observed in many conditions, especially in ag-
ing, apoptosis and carcinogenesis (Goebel et al., 2005; Liu
et al., 2003; Mehra et al., 2007; Takeuchi et al., 2004). So
far, the exact content of human mtDNA in different cells
and tissues remains unclear. Two studies developed multi-
plex assays to analyse nDNA and mtDNA simultaneously
for forensic medicine (Alonso et al., 2004; Walker et al.,
2005). In our study, we were able to use the GAPDH gene
as a housekeeping gene to analyse the quantities of
mtDNA. The aim of this study was to develop a rapid, sim-
pleandaccuratemultiplexreal-timePCRforthedirectsyn-
chronized analysis of ccf mtDNA and ccf nDNA, which
mayprovideaplatformforfurtherinvestigationsleadingto
abetterunderstandingofthebiologyofccfmtDNAandccf
nDNA on large-scale sample sizes.
It is known that ancient mtDNA sequences, also
termed as nuclear pseudogenes, are present in the human
nuclear genome as multiple copies. Woischnik and Moraes
(2002) found up to 612 nuclear integrations. Their homo-
logywiththecurrentmtDNAwasupto99%.Anaccidental
co-amplification of these nuclear copies of mitochondrial
genes might bias the results (Wallace et al., 1997). We
tested the specificity by using the mitochondria-negative
cell line 0, and no mtDNA signals were detected in this
cell line by real-time multiplex PCR.
Based on the importance of quantification of both
mtDNA and nDNA in life science, we developed a rapid,
accurate, simple and low-cost approach that enables the si-
multaneous identification of physiological and pathogenic
mtDNAandnDNAvariants.Sincetherearenocommercial
kitsforccfmtDNAextractionfromserumandplasmasam-
ples, we, for the first time, compared three different DNA
extraction methods for co-extracting nDNA and mtDNA
from plasma and serum. We were also the first ones to ex-
aminetheefficienciesofthetwoassaysinasingletube.Af-
ter calculating the comparative efficiencies we could use
the nDNA level as a reference to assess the relative quanti-
ties of mtDNA, which can simplify the calculation of
mtDNAcontent.Themethodissimpleanddoesnotrequire
generating standard curves, which often result in errors due
to dilution inaccuracy. This method can be considered a
standardapproachforwidelyquantifyingbothmtDNAand
nDNA in different kinds of samples.
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